Novartis drums up EU launch plans as CHMP gives thumbs up to Spark's gene therapy Luxturna
Nine months after the FDA gave its landmark OK for Spark Therapeutics’ trailblazing gene therapy Luxturna, European regulators have signaled that they are ready to greenlight the vision loss treatment, too.
The team at Spark $ONCE isn’t the only ones celebrating the positive opinion from the Committee for Medicinal Products for Human Use: Novartis, which grabbed ex-US rights to Luxturna earlier this year in a $170 million deal, will be commercializing the therapy once it’s approved in Europe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.